Physician profile
Gregory Brennan
NPI 1689017105
$6,606.44
in general payments reported to CMS, 2019-2025
38 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $215 · 2021: $477 · 2022: $1,055 · 2023: $1,492 · 2024: $1,721 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $54.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,543.13 |
| Education | $54.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,564.55 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $736.00 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $460.46 | 2021-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $377.75 | 2022-2025 | Dupixent |
| Pfizer INC. | $316.23 | 2020-2025 | |
| Genzyme Corporation | $302.38 | 2022-2025 | |
| Qol Medical, LLC | $255.57 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $251.25 | 2020-2025 | Entyvio, Eohilia |
| Conmed Corporation | $235.41 | 2019-2023 | Conmed Biliary, System 2450 |
| Celgene Corporation | $222.77 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $213.91 | 2021-2024 | Dificid |
| Covidien Lp | $189.30 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $138.05 | 2020-2024 | Linzess |
| Madrigal Pharmaceuticals | $126.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $117.96 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.35 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $100.56 | 2024-2025 | Voquezna |
| Ethicon US, LLC | $100.23 | 2022 | |
| Janssen Scientific Affairs, LLC | $92.59 | 2023 | Remicade, Tremfya, Stelara |
| Ardelyx, INC. | $90.60 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $90.25 | 2021-2025 | General - Hemostasis |
| Redhill Biopharma INC. | $81.81 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Ferring Pharmaceuticals INC. | $59.86 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $59.62 | 2020-2022 | |
| Celltrion USA INC. | $57.69 | 2024-2025 | Vegzelma |
| Stryker Corporation | $49.69 | 2025 | Neptune |
| Nestle Healthcare Nutrition INC. | $31.88 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $31.25 | 2025 | Zenpep |
| Gilead Sciences, INC. | $30.26 | 2025 | |
| Medtronic, INC. | $24.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.77 | 2022 | |
| Vivus LLC | $16.83 | 2025 | Pancreaze |
| Alnylam Pharmaceuticals INC. | $14.20 | 2025 | Givlaari |
| Alfasigma USA, INC. | $13.86 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.57 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $8.84 | 2020 | |
| Echosens North America, INC. | $6.01 | 2025 | Fibroscan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,912.34 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.